About Soligenix, Inc
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn’s disease and acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; and ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. Address: 29 Emmons Drive, Princeton, NJ, United States, 08540
Soligenix, Inc News and around…
Latest news about Soligenix, Inc (SNGX) common stock and company :
Gainers Genocea Biosciences (NASDAQ:GNCA) shares moved upwards by 70.9% to $0.1 during Wednesday's pre-market ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines." The allowed claims are directed to unique, proprietary compositions and me
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update SGX302 for Psoriasis Soligenix, Inc. (NASDAQ:SNGX) will be developing synthetic hypericin (the active ingredient in HyBryte) as part of a photodynamic therapy in mild-to-moderate psoriasis patients under the research name SGX302. Psoriasis is a common, chronic, noncontagious, multisystem inflammatory condition that
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming H.C. Wainwright Global Investment Conference. The conference will be held May 23 through 26, 2022 with presentations, one-on-one meetings, and networking. The on-demand presentation will be available Tue
On Friday, 153 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: Vodafone Group ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2022.
Gainers Salarius Pharmaceuticals (NASDAQ:SLRX) stock increased by 24.7% to $0.2 during Wednesday's after-market session. Salarius ...
On Wednesday, 807 companies reached new 52-week lows. Things to Consider About Today's 52-Week Lows: Amazon.com ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received approximately $1.4 million, net of transaction costs, in non-dilutive funding via multiple government tax programs.
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update HyBryte™ NDA Anticipated in 2022 Soligenix, Inc. (NASDAQ:SNGX) previously completed a Phase 3 clinical trial of HyBryte™ (SGX301, synthetic hypericin) in patients with cutaneous T cell lymphoma (CTCL). The FLASH ( F luorescent L ight A ctivated S ynthetic H ypericin) trial was a randomized, double blind, placebo
Soligenix (NASDAQ:SNGX) reported its Q4 earnings results on Tuesday, March 29, 2022 at 07:00 AM. Here's what investors ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2021.
Soligenix Inc(NASDAQ: SNGX) announced theresults of a booster vaccination studyusing CiVax (heat-stable COVID-19 ...
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 31.0% to $1.31 during Thursday's pre-market session. The ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the results of a booster vaccination study using CiVax™ (heat stable COVID-19 subunit vaccine program) in non-human primates (NHPs) demonstrating rapid enhancement of neutralizing antibody responses to SARS-CoV-2, including against Delta and Omicron variants. The NHPs had b
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
SG Blocks, Inc. (NASDAQ: SGBX) (“SG Blocks” or the “Company”), a leading developer, designer, and fabricator of modular structures, and Moliving Inc., the world’s first luxury nomadic hospitality solution, today announced SG Blocks is leading Moliving’s seed round. Moliving, which is a developer's solution conceived to disrupt the modular living and hospitality industries, offers hoteliers and landowners the opportunity to adjust room inventory to match demand in real time with minimal disruption to the environment.
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Senior Vice President and Chief Financial Officer, Jonathan Guarino, has been invited to attend the Q1 Virtual Investor Summit. The conference will take place March 8-9, 2022, and includes one-on-one meetings and a Company presentation with Q&A at 1:15 P.M. EST on
Princeton, New Jersey--(Newsfile Corp. - March 1, 2022) - Soligenix, Inc. (NASDAQ: SNGX) today announced that Jonathan Guarino, Senior Vice President & Chief Financial Officer will be attending the Q1 Virtual Investor Summit. During the presentation, Soligenix’s Senior Vice President & Chief Financial Officer, Jonathan Guarino, will review the Company's robust pipeline and highlight upcoming potential value drivers, including an NDA filing to the FDA later this year. The presentation will be web
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the BIO CEO & Investor Conference taking place February 14-17, 2022. The presentation will be available to registered conference attendees for on-demand vie
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Multiple Milestones Ahead in 2022 Soligenix, Inc. (NASDAQ:SNGX) has a number of important milestones and events ahead in 2022 as the company continues to develop its pipeline of specialized biotherapeutics and public health solutions. HyBryte™ Soligenix completed a Phase 3 clinical trial of HyBryte™ (SGX301,
New York, New York--(Newsfile Corp. - January 12, 2022) - PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a US-based late-stage biopharmaceutical company, issued a corporate update this week with good news for their shareholders. Despite supply-chain delays in receiving the active pharmaceutical ingredient for SGX301, aka HyBryte™, the company is still on track to file a new drug application with the FDA in the latter half of 2022. HyBryte™ is an early-stage treatment for ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming virtual investor conferences below.
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that dusquetide is effective at reducing tumor size in nonclinical xenograft models. Recent studies, recapitulating results from previously published studies, have confirmed the efficacy of dusquetide as a stand-alone and combination anti-tumor therapy, with radiation, chem
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows ...
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...
Soligenix, Inc (SNGX) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
